Factors predicting the outcome of conservatively treated adenocarcinoma in situ of the uterine cervix: An analysis of 166 cases

Silvano Costa, Simona Venturoli, Giovanni Negri, Mario Sideri, Mario Preti, Martina Pesaresi, Adriana Falasca, Daniela Barbieri, Marialuisa Zerbini, Donatella Santini, Maria Teresa Sandri, Bruno Ghiringhello, Nadia Caroppo Venturini, Stina Syrjänen, Kari Syrjänen

Research output: Contribution to journalArticlepeer-review


Objective: The present study assessed the clinical outcome of patients conservatively treated for cervical adenocarcinoma in situ (AIS) and their predictive factors using univariate and multivariate population averaged (PA) generalized estimating equation (GEE) model in a longitudinal setting. Methods: A series of 166 consecutive women (mean age 39.8 yrs; range 23-63 yrs) underwent conservative treatment of AIS as the primary treatment and were followed-up (mean 40.9 mo) using colposcopy, PAP-smear, biopsy and HPV-testing with Hybrid Capture 2. Results: Hysterectomy was performed as part of the primary management in 47 patients, who were excluded from the follow-up (FU) analysis. Out of 119 women closely followed-up, additional therapeutic procedures were performed in 69. At study conclusion, 7 patients (5.9%) showed persistent disease, while 8 (6.7%) had progressed to invasive adenocarcinoma (AC). Positive HR-HPV test was the only independent predictor of disease recurrence (adjusted OR = 2.72; 95%CI 1.08-6.87), and together with free cone margins (OR = 0.20; 95%CI 0.04-0.92), HR-HPV positivity was also the single most powerful predictor of disease progression to AC, with OR = 3.74; 95%CI 1.84-7.61 (p = 0.0001) in multivariate PA-GEE. Conclusions: These results suggest that testing HR-HPV positive at any time point during FU is the most significant independent predictor of progressive disease, while showing free margins in cone has a significant protective effect against progression to AC. Furthermore, because 4.3% women with persistent, recurrent or progressive disease experienced a late (5th and 6th FU) diagnosis of HG-CGIN or microinvasive AC, a close surveillance should be scheduled for at least three years in conservatively treated AIS patients.

Original languageEnglish
Pages (from-to)490-495
Number of pages6
JournalGynecologic Oncology
Issue number3
Publication statusPublished - Mar 2012


  • Adenocarcinoma in situ
  • Conservative treatment
  • Follow-up, test performance
  • Predictive factors, PA-GEE models

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology


Dive into the research topics of 'Factors predicting the outcome of conservatively treated adenocarcinoma in situ of the uterine cervix: An analysis of 166 cases'. Together they form a unique fingerprint.

Cite this